Latest clinical trial data on finerenone in the treatment of diabetic nephropathy

Finerenone (Finerenone) is a new type of non-steroidal selective mineralocorticoid receptor antagonist that has attracted much attention in the treatment of diabetic kidney disease (DKD) in recent years. The latest clinical trial data show that fenelinone can significantly slow the deterioration of renal function in patients with diabetic nephropathy and reduce the risk of related cardiovascular events. The drug reduces inflammation and fibrosis by inhibiting mineralocorticoid receptors, thereby protecting kidney function and improving patient prognosis.

In a large multi-center randomized controlled trialFIDELIO-DKD, fenelidone showed significantly better efficacy than traditional treatment options. The study included approximately 5700 patients with type 2 diabetes and chronic kidney disease. The results showed that compared with the placebo group, the risk of the primary endpoint event was reduced by 18% in the fenelidone group. These endpoints include renal failure, a sustained decrease in estimated glomerular filtration rate (eGFR) of more than 40% and kidney-related death. In addition, fenelidone also reduced the occurrence of adverse cardiovascular events, showing dual cardio-renal protective effects.

Real-world studies at home and abroad have also verified the application value of fenelidone in actual clinical practice. For example, in a study conducted in China, after patients were treated with fenelidone for 6 months, the urinary albumin/creatinine ratio (UACR) decreased significantly, with the maximum decrease reaching 73%. This shows that fenelidone can not only protect renal function, but also effectively reduce proteinuria and delay the progression of kidney disease. It was well tolerated by patients and had a low incidence of side effects, with the main concern being the risk of hyperkalemia.

In summary, fenelidone has demonstrated significant clinical benefits in the treatment of diabetic nephropathy. It is suitable as an important complement to existing nephroprotective drugs (such as RAS inhibitors and SGLT2 inhibitors), helping to further reduce the risk of renal events and cardiovascular events in patients. In the future, with the accumulation of more clinical data, fenelidone is expected to become an important part of the treatment of diabetic nephropathy, bringing better quality of life and improved prognosis to patients.

Reference materials:https://www.kerendia.com/

xa0